Swiss Re AG (0QL6)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 153.53 |
|---|---|
| 52-week range | 114.20 – 154.30 |
| Return, 1 month / 3 months | +8.0% / +13.7% |
| Return, 1 year / 3 years | +1.6% / +57.9% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 21.0% |
| Worst drawdown (1 year) | -25.3% |
| Average daily value traded | 20.55M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Swiss Re AG is a reinsurance company based in Zurich, Switzerland. It provides reinsurance and risk transfer solutions to insurance companies and large corporate customers around the world, covering property, casualty, life and health risks. The company also offers commercial insurance and related services to businesses, helping them manage large or unusual risks. Its clients include insurers, multinational corporations and public sector organisations that rely on it to absorb risk and provide capacity for their own policies.
Swiss Re AG trades under the code 0QL6 on the London Stock Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Swiss Re AG (0QL6) trades on the London Stock Exchange in UK. It last closed at GBP 153.53 on 27 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 248 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.6% and over the last three months it rose 13.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.6% | ||
| From 52-week high | -0.5% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 13.7% | ||
| 6-month return | 19.8% | ||
| 12-month return, skipping the last month | -5.9% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.3% | ||
| Liquidity | 79 · Strong | Trades actively. | |
| Average daily value traded | 20.55M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.9% |
|---|---|
| 1 month | +8.0% |
| 3 months | +13.7% |
| 6 months | +19.8% |
| 1 year | +1.6% |
| 3 years | +57.9% |
| 5 years | +80.4% |
Signals
| 50-day / 200-day average | 142.56 / 131.69 |
|---|---|
| Golden / death cross (60 days) | Golden, 50 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.94 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Apr 2026 | GBX 0.0630 |
| 15 Apr 2025 | GBX 0.0601 |
| 16 Apr 2024 | GBX 0.0622 |
| 14 Apr 2023 | GBX 0.0572 |
| 19 Apr 2022 | GBX 0.0590 |
| 20 Apr 2021 | GBX 0.0590 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.